Halia Therapeutics develops allosteric inhibitors targeting the NLRP3 inflammasome to disrupt chronic inflammation associated with neurodegenerative and inflammatory diseases. Their therapies aim to reduce inflammation, potentially improving quality of life and longevity for patients suffering from conditions such as Alzheimer's, rheumatoid arthritis, and obesity.
Funding
$56.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic inflammation, driven by dysregulation of the NLRP3 inflammasome, contributes to the pathology of numerous diseases, including neurodegenerative disorders, autoimmune conditions, and metabolic diseases. Current treatment options often fail to adequately address the underlying inflammatory processes, leading to disease progression and reduced quality of life.
Solution
Halia Therapeutics develops allosteric inhibitors that target and disrupt the NLRP3 inflammasome, a key driver of chronic inflammation. By selectively inhibiting NLRP3, Halia's therapies aim to reduce the production of pro-inflammatory signaling proteins and reset the inflammatory pathway. This approach has the potential to treat or prevent neurodegenerative and inflammatory diseases, ultimately improving patient outcomes and promoting longevity. Halia is currently developing investigational treatments for Alzheimer's disease, rheumatoid arthritis, obesity, Parkinson's disease, and cancer.
Target Audience
The primary target audience includes patients suffering from chronic inflammatory diseases such as Alzheimer's, rheumatoid arthritis, obesity, and Parkinson's, as well as healthcare providers specializing in these conditions.
Features
- Allosteric inhibition of the NLRP3 inflammasome to modulate the inflammatory response
- Development of brain-penetrant compounds for neurodegenerative diseases like Alzheimer's and Parkinson's
- Investigational treatments for rheumatoid arthritis and post-surgical pain
- Programs targeting obesity, including combination therapies with GLP-1 agonists
- Potential pathways to prevent the onset of cancer